9.80
0.07 (0.77%)
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bearish |
| Biotechnology (Global) | Mixed | Bearish | |
| Stock | Liquidia Corporation | Bearish | Bullish |
Stockmoo Score
|
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also generates revenue from the sale of Treprostinil Injection through an agreement between its subsidiary and the manufacturer. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Patient Square Capital Lp | 30 Jun 2024 | 7,182,532 |
| Findell Capital Management Llc | 30 Jun 2024 | 2,400,000 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 29.00 (HC Wainwright & Co., 196.07%) | Buy |
| Median | 25.00 (155.23%) | |
| Low | 19.00 (Needham, 93.98%) | Buy |
| Average | 24.60 (151.15%) | |
| Total | 5 Buy | |
| Avg. Price @ Call | 9.72 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| HC Wainwright & Co. | 23 Aug 2024 | 29.00 (196.07%) | Buy | 9.97 |
| 20 Aug 2024 | 29.00 (196.07%) | Buy | 9.60 | |
| Needham | 22 Aug 2024 | 19.00 (93.98%) | Buy | 9.63 |
| 19 Aug 2024 | 25.00 (155.23%) | Buy | 9.79 | |
| B of A Securities | 20 Aug 2024 | 23.00 (134.81%) | Buy | 9.60 |
| BTIG | 20 Aug 2024 | 25.00 (155.23%) | Buy | 9.60 |
| 19 Aug 2024 | 25.00 (155.23%) | Buy | 9.79 | |
| Raymond James | 19 Aug 2024 | 27.00 (175.65%) | Buy | 9.79 |
| 16 Aug 2024 | 27.00 (175.65%) | Buy | 14.11 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| CALIGAN PARTNERS LP | 9.72 | - | 1,123,595 | 10,921,343 |
| MANNING PAUL B | 9.72 | - | 337,078 | 3,276,398 |
| Aggregate Net Quantity | 1,460,673 | |||
| Aggregate Net Value ($) | 14,197,742 | |||
| Aggregate Avg. Buy ($) | 9.72 | |||
| Aggregate Avg. Sell ($) | - | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| CALIGAN PARTNERS LP | Director | 12 Sep 2024 | Acquired (+) | 1,123,595 | 9.72 | 10,921,343 |
| MANNING PAUL B | Director | 12 Sep 2024 | Buy (+) | 337,078 | 9.72 | 3,276,398 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2024 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |